Remiges created our second seed stage company based on intellectual properties from the Japanese academia
We Remiges Biopharma Fund recognize we have a significant mission to create de novo companies based on intellectual properties from Japanese academic institutions.
As our second de novo company, we have established a Newco in the United State and signed a licensing agreement for the intellectual properties around the inventions discovered by researchers at Clinical Division of Diabetes and Metabolic Diseases, The University of Tokyo Hospital.
Under our unique model, Remiges has a virtual drug development team involving multiple experts having in-depth preclinical and clinical development experience.
The virtual development team is conducting an early stage development using external contract research organizations under a development plan that Remiges and the scientists discussed and established.
Upon achievement of predetermined development milestones, we will recruit managers and inject additional capital into the company for future development of the assets.